Epitome Therapeutics
PrivateLast Round
Grant
Jun 30, 2026
Total Funding Raised
$2.28M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Epitome Therapeutics is a biotechnology company developing CADENCE, a programmable platform for precise and durable activation of endogenous genes to treat severe liver and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epitome Therapeutics Comparables
Compare Epitome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| nChroma Bio | 82% | |
| Tune Therapeutics | 79% | |
| Chroma Medicine | 78% |
Epitome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 30, 2026 |
Epitome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Austria Wirtschaftsservice | Grant |
| xista science ventures | Grant |
| Caesar Ventures | Grant |
| FFG Austrian Research Promotion Agency | Grant |
| xista science ventures | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
$2.3M round led by Caesar Ventures and xista science ventures.
Recent news
Latest coverage and updates
- is_developingJul 24, 2026
Epitome Tx was planning to develop technologies designed to restore gene expression to therapeutically meaningful levels on Jul 24th '26.
- is_developingJul 24, 2026
Epitome Tx is developing technologies designed to restore gene expression to therapeutically meaningful levels.
- is_developingJun 30, 2026
Epitome Tx is developing therapeutic approach based on the precise regulation of gene expression on Jun 30th '26.
- receives_financingJun 30, 2026
Epitome Tx received financing of $2.29M in Pre Seed on Jun 30th '26.
Epitome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Epitome Therapeutics's valuation, stock price, and market status.
Is Epitome Therapeutics a public or private company?
Epitome Therapeutics is a private company.
What is the current stock price of Epitome Therapeutics?
Epitome Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Epitome Therapeutics worth (valuation)?
Valuation information for Epitome Therapeutics is not publicly available.
Can I buy Epitome Therapeutics stock?
Epitome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Epitome Therapeutics's last funding round?
Epitome Therapeutics's most recent funding round was Pre Seed on June 30, 2026.
Who are the main investors in Epitome Therapeutics?
Key investors in Epitome Therapeutics include Caesar Ventures, xista science ventures.
Will Epitome Therapeutics IPO soon?
No public IPO plans have been announced for Epitome Therapeutics.
How can I track Epitome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Epitome Therapeutics's secondary market activity and sign up for updates.